KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biolife Solutions (BLFS) EBITDA Margin (2016 - 2025)

Biolife Solutions (BLFS) has disclosed EBITDA Margin for 16 consecutive years, with 7.17% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 358.0% to 7.17% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 17.26% through Dec 2025, down 1126.0% year-over-year, with the annual reading at 17.26% for FY2025, 1126.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 7.17% at Biolife Solutions, up from 0.32% in the prior quarter.
  • The five-year high for EBITDA Margin was 7.17% in Q4 2025, with the low at 218.96% in Q4 2022.
  • Average EBITDA Margin over 5 years is 45.58%, with a median of 25.4% recorded in 2022.
  • The sharpest move saw EBITDA Margin plummeted -17429bps in 2022, then soared 15254bps in 2023.
  • Over 5 years, EBITDA Margin stood at 49.5% in 2021, then tumbled by -342bps to 218.96% in 2022, then soared by 43bps to 125.43% in 2023, then skyrocketed by 103bps to 3.59% in 2024, then skyrocketed by 100bps to 7.17% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 7.17%, 0.32%, and 65.47% for Q4 2025, Q3 2025, and Q2 2025 respectively.